Company profile: Kriya Therapeutics
1.1 - Company Overview
Company description
- Provider of gene therapies for ophthalmology, neurology, and metabolic diseases, including KRIYA-825 for geographic atrophy (inhibiting C3/C5; one-time suprachoroidal), KRIYA-586 for thyroid eye disease (blocking IGF1 receptor), KRIYA-839 for diabetes (insulin and glucokinase), KRIYA-497 for NASH (FGF21), and KRIYA-748 and KRIYA-382 for trigeminal neuralgia and focal epilepsy via chemogenetically gated ion channels.
Products and services
- KRIYA-497: Kriya Therapeutics engineers a custom-engineered, single-dose gene therapy expressing native FGF21, administered intramuscularly to reduce fibrosis and improve metabolic profile in NASH
- KRIYA-825: Kriya Therapeutics develops an ophthalmic-grade, single-dose suprachoroidal gene therapy that inhibits complement C3 and C5 to treat Geographic Atrophy
- KRIYA-839: Kriya Therapeutics produces a therapeutic-grade gene therapy delivered intramuscularly that expresses insulin and glucokinase to enable durable glycemic control for Diabetes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kriya Therapeutics
EnPlusOne Biosciences
HQ: United States
Website
- Description: Provider of an ezRNA platform enabling incorporation of standard and non-standard nucleobases and their modifications, supporting installation of standard and phosphorothioated backbones, and integrating 2' modifications essential for siRNA therapeutics and novel variants. Offers 3' modifications including linkers and chain terminators for emerging RNA therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EnPlusOne Biosciences company profile →
ReNAgade Therapeutics
HQ: United States
Website
- Description: Provider of RNA therapeutic platforms, offering RNA delivery systems to target previously inaccessible cells, an RNA coding platform (with Orna Therapeutics) for reprogramming cells, proprietary gene editing technology for permanent gene correction, and an all-RNA Gene Therapy 2.0 platform enabling exon and large gene insertions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReNAgade Therapeutics company profile →
Skyhawk Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics and RNA-targeting platforms that correct RNA expression. Offers SKYSTAR for RNA target assessment and prioritization; SKYLIBRARY of RNA-targeting compounds; SKYSEQ multiplex screening for testing multiple RNA targets; and SKYAI machine-learning tools for advancing RNA splicing modulators. Pipeline includes SKY-0515, a small molecule RNA splicing modifier for Huntington’s disease in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Skyhawk Therapeutics company profile →
Mirus Bio
HQ: United States
Website
- Description: Provider of nucleic acid-based technologies and gene transfer methods for the pharmaceutical business, including a proprietary RNAi delivery platform and tools for gene expression and biotherapeutic protein. Products include TransIT-VirusGEN for AAV/lentivirus vector production in research and clinical applications, RevIT AAV Enhancer, TransIT-LT1 transfection reagent, and GMP-grade ancillary materials for cell and gene therapy manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirus Bio company profile →
Agilis Biotherapeutics
HQ: United States
Website
- Description: Provider of DNA-based therapeutics for genetic disorders, focused on rare central nervous system diseases caused by single-gene defects. Its technology enables precise targeting and restoration of lost gene function while avoiding unintended off-target effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agilis Biotherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kriya Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kriya Therapeutics
2.2 - Growth funds investing in similar companies to Kriya Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kriya Therapeutics
4.2 - Public trading comparable groups for Kriya Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →